Reduction in surface urokinase receptor forces malignant cells into a protracted state of dormancy

Journal of Cell Biology

Volumn 137, Issue 3, 1997, Pages 767-777

  Yu, W ^a   Kim, J ^a   Ossowski, L ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ACTIN; CELL SURFACE RECEPTOR; PLASMINOGEN ACTIVATOR; UROKINASE;

APOPTOSIS; CANCER CELL; CELL CYCLE S PHASE; CELL SURFACE; CHICK EMBRYO; CHORIOALLANTOIS; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; METASTASIS; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; RECEPTOR DENSITY; REVIEW; SQUAMOUS CELL CARCINOMA;

APOPTOSIS; CELL DIVISION; DNA, NEOPLASM; DOWN-REGULATION; HUMANS; NECROSIS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; RECEPTORS, CELL SURFACE; RNA, ANTISENSE; TUMOR CELLS, CULTURED; URINARY PLASMINOGEN ACTIVATOR;

EID: 0030956119     PISSN: 00219525     EISSN: None     Source Type: Journal    
DOI: 10.1083/jcb.137.3.767     Document Type: Review

References (50)

1. Axelrod, J.H., R. Reich, and R. Miskin. 1989. Expression of human recombinant plasminogen activators enhances invasion and experimental metastasis of H-ras-transformed NIH 3T3 cells. Mol. Cell. Biol. 9:2133-2141.
2. Bianchi, E., R.L. Cohen, A.T. Thor, R.F. Todd, III, I.F. Mizukami, D.A. Lawrence, B.M. Ljung, M.A. Shuman, and H.S. Smith. 1994. The urokinase receptor is expressed in invasive breast cancer but not in normal breast tissue. Cancer Res. 54:861-866.
3. Blasi, F. 1993. Urokinase and urokinase receptor: a paracrine/autocrine system regulating cell migration and invasiveness. BioEssays. 15:105-111.
4. Brooks. P.C., J.M. Lin, D.L. French, and J.P. Quigley. 1993. Subtractive immunization yields monoclonal antibodies thai specifically inhibit metastasis. J. Cell Biol. 122:1351-1359.
5. Busso, N., S.M. Masur, D. Lazega, S. Waxman, and L. Ossowski. 1994. Induction of cell migration by pro-urokinase binding to its receptor: possible mechanism for signal transduction in human epithelial cells. J. Cell Biol. 126: 259-270.
6. Cajot, J.-F., W.-D. Schleuning, R.L. Medcalf, R.J. Bamat, J. Testa, L. Liebermann, and B. Sordat. 1989. Mouse L-cells expressing human prourokinase type PA: effects on extracellular matrix degradation and invasion. J. Cell Biol. 109:915-929.
7. Carriero, M.V., P. Franco, S. Del-Vecchio, O. Massa, G. Botti, G. D'Aiuto, M.P. Stoppelli, and M. Salvatore. 1994. Tissue distribution of soluble and receptor bound urokinase in human breast cancer using a panel of monoclonal antibodies. Cancer Res. 54:5445-5454.
8. Crowley, W.C., R.L. Cohen, B.K. Lucas, G. Liu, M.A. Shuman, and A.D. Levinson. 1993. Prevention of metastasis by inhibition of the urokinase receptor. Proc. Natl. Acad. Sci. USA. 90:5021-5025.
9. Dano, K., P.A. Andreasen, J. Grondahl-Hansen, P. Kristensen. L. Nielsen, and L. Skriver. 1985. Plasminogen activators, tissue degradation and cancer Adv. Cancer Res. 44:139-266.
10. DeBruin, P.A., G. Griffioen, H.V. Verspaget, and J.H. Verheijen. 1987. Plasminogen activators and tumor development in the human colon. Activity levels in normal mucosa, adenomateous tissue, polyps and adenocarcinomas Cancer Res. 47:4654-4657.
11. Duffy, M.J., D. Reilly, C. O'Sullivan, N. O'Higgins, and J.J. Fennely. 1990. Urokinase plasminogen activator and prognosis in breast cancer. Lancet. 13: 108-111.
12. Ellis, V., N. Behrendt, and K. Dano. 1991. Plasminogen activation by receptor-bound urokinase. A kinetic study with both cells-associated and isolated receptor. J. Biol. Chem. 266:12752-12758.
13. Grondahl-Hansen, J., E. Ralfkiaer, L. Kirkeby, P. Kristensen, L.R. Lund, and K. Dano. 1991. Localization of urokinase-type plasminogen activator in stromal cells in adenocarcinomas of the colon in humans. Am. J. Pathol. 138: 111-117.
14. Gunning, P., J. Leavitt, G. Muscat, S.-Y. Ng, and L. Kedes. 1987. A human β-actin expression vector system directs high-level accumulation of antisense transcripts. Proc. Natl. Acad. Sci. USA. 84:4831-4825.
15. Hearing, V.J., L.W. Law, A. Corti, E. Appella, and F. Blasi. 1988. Modulation of metastatic potential by cell surface urokinase of murine melanoma cells. Cancer Res. 48:1270-1278.
16. Holmgren, L., M.S. O'Reilly, and J. Folkman. 1995. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat. Med. 1:149-153.
17. Huang, Y., B.M. Scher, and S. Waxman. 1995. Combination cytotoxic-differentiation therapy-induced apoptosis correlates with decreased intracellular pH and activation of endonucleases. Mol. Cell. Diff. 3:241-260.
18. Janicke, F., M. Schmidt, A. Hollrieder, R. Babic, K. Ulm, W. Gossner, and H. Graeff. 1990. Urokinase-type plasminogen activator (uPA) is a predictor of early relapse in breast cancer. Fibrinolysis. 4:69-78.
19. Kasid, U., A. Pfeiffer, T. Breannan, M. Beckett, R.R. Weichselbaum, A. Dritschillo, and G.E. Mark. 1989. Effect of antisense c-raf-1 on tumorigenicity and radiation sensitivity of a human squamous carcinoma. Science (Wash. DC). 243:1354-1356.
20. Kobayashi, H., J. Gotoh, M. Fujie, H. Shinohara, N. Moniwa, and T. Terao. 1994. Inhibition of metastasis of Lewis lung carcinoma by a synthetic peptide within growth factor domain of urokinase in the experimental and spontaneous metastasis model. Int. J. Cancer. 57:727-733.
21. Kook, Y.-H., J. Adamski, A. Zelent, and L. Ossowski. 1994. The effect of antisense inhibition of urokinase receptor in human squamous cells carcinoma on malignancy. EMBO (Eur. Mol. Biol. Organ.) J. 13:3983-3991.
22. Kyprianou, N., and J.T. Isaacs. 1988. Activation of programmed cell death in the rat ventral prostate after castration. Endocrinology. 122:552-562.
23. Mars, W.M., M.L. Liu, R.P. Kitson, R.H. Goldfarb, M.K. Gabauer, and G.K. Michalopoulos. 1995. Immediate early detection of urokinase receptor after partial hepatectomy and its implication for liver regeneration. Hepatology. 21:1695-1701.
24. Mignatti, P., and D. Rifkin. 1993. Biology and biochemistry of proteinases in tumor invasion. Physiol. Rev. 73:161-195.
25. Mignatti, P., E. Robbins, and D.B. Rifkin. 1986. Tumor invasion through the human amniotic membrane: requirement for a proteinase cascade. Cell. 47: 487-498.
26. Mira-y-Lopez, R., and L. Ossowski. 1987. Hormonal modulation of plasminogen activator: an approach to prediction of human breast tumor responsiveness. Cancer Res. 47:3558-3564.
27. Moroni, M.C., M.C. Willingham, and L. Beguinot. 1992. EGF-R antisense blocks expression of the epidermal growth factor receptor and suppresses the transformed phenotype of a human carcinoma cell line. J. Biol. Chem. 267:2714-2722.
28. Naldini, L., E. Vigna, A. Bardelli, A. Follenzi, F. Galimi, and P.M. Comoglio. 1995. Biological activation of pro-HGF (hepatocyte growth factor) by urokinase is controlled by a stoichiometric reaction. J. Biol. Chem. 270:603-611.
29. Odekon, L.E., Y. Sato, and D.B. Rifkin. 1992. Urokinase-type plasminogen activator mediates basic fibroblast growth factor-induced bovine endothelial cell migration independent of its proteolytic activity. J. Cell Physiol. 150: 258-263.
30. Ossowski, L. 1988. In vivo invasion of modified membrane by tumor cells: the role of cell surface-bound urokinase. J. Cell Biol. 107:2437-2445.
31. Ossowski, L., and E. Reich. 1983. Antibodies to plasminogen activator inhibit human tumor metastasis. Cell. 35:611-619.
32. Ossowski, L., G. Clunie, T. Masucci, and F. Blasi. 1991. In vivo paracrine interaction between urokinase and its receptor: effect on tumor cell invasion. J. Cell Biol. 115:1107-1112.
33. Ossowski, L., H. Russo-Payne, and E.L. Wilson. 1991. Inhibition of urokinase-type plasminogen activator by antibodies: the effect on dissemination of a human tumor in the nude mouse. Cancer Res. 51:274-281.
34. Pepper, M.S., J.-D. Vassalli, R. Montesano, and L. Orci. 1987. Urokinase-type plasminogen activator is induced in migrating capillary endothelial cells. J. Cell Biol. 105:2535-2541.
35. Plow, E.F., D.E. Freaney, J. Plescia, and L.A. Miles. 1986. The plasminogen system and cell surfaces: evidence for plasminogen and urokinase receptors on the same cell type. J. Cell Biol. 103:2411-2420.
36. Pyke, C., P. Kristensen, E. Ralkfiaer, E. Ronne, J. Grondahl-Hansen, J. Eriksen, F. Blasi, and K. Dano. 1991-Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells in invasive foci in human colon adenocarcinomas. Am. J. Path. 138:1059-1067.
37. Quax, P.H.A., N. Pedersen, M.T. Masucci, E.J.D. Weeningverhoeff, K. Dano, J.H. Verheijnen, and F. Blasi. 1991. Complementation between urokinase-producing and receptor producing cells in extracellular matrix degradation. Cell Regul. 2:793-803.
38. Rabbani, S.A., A.P. Mazar, S.M. Bernier, M. Haq, I. Bolivar, J. Henkin, and D. Goltzman. 1992. Structural requirements for the growth factor activity of the amino-terminal domain of urokinase. J. Biol. Chem. 267:14151-14156.
39. Rao, N.K., G.P. Shi, and H.A. Chapman. 1995. Urokinase is a multifunctional protein: influence of receptor occupancy on macrophage gene expression. J. Clin. Invest. 96:465-474.
40. Roldan, A.L., M.V. Cubellis, M.T. Masucci, N. Behrendt, L.R. Lund, K. Dano, E. Appella, and F. Blasi. 1990. Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis. EMBO (Eur. Mol. Biol. Organ.) J. 9:467-474.
41. Saksela, O., and D.B. Rifkin. 1990. Release of bFGF-heparan sulfate complexes from endothelial cells by plasminogen activator mediated proteolytic activity. J. Cell Biol. 110:767-775.
42. Schlechte, W., G. Murano, and D. Boyd. 1989. Examination of the role of urokinase receptors in human colon cancer mediated laminin degradation. Cancer Res. 49:6064-6069.
43. Stahl, A., and B.M. Mueller. 1994. Binding of urokinase to its receptor promotes migration and invasion of human melanoma cells in vitro. Cancer Res. 54:3066-3071.
44. Stephens, R.W., J. Pollanen, H. Tapiovara, K.-C. Leung, P.-S. Sim, E.-M. Salonen, E. Ronne, N. Behrendt, K. Dano, and A. Vaheri. 1989. Activation of pro-urokinase and plasminogen on human sarcoma cells: a proteolytic system with surface-bound reactants. J. Cell Biol. 108:1987-1995.
45. Stopelli., M.P., C. Tacchetti, M.V. Cubellis, A. Corti, V.J. Hearing, G. Cassani, E. Appella, and F. Blasi. 1986. Autocrine saturation of prourokinase receptors on human A431 cells. Cell. 45:657-684.
46. Testa, J.E., and J.P. Quigley. 1990. The role of plasminogen activator in aggressive tumor behavior. Cancer Metastasis Rev. 9:353-367.
47. Toolan, H.W. 1954. Transplantable human neoplasms maintained in cortisone-treated laboratory animals: HS#1, H.Ep.#l, H.Ep.#2, H.Ep.#3 and H.Emb.#1. Cancer Res. 14:660-666.
48. Vaillancourt, L., B. Tetu, Y. Fradet, A. Dupont, J. Gomez, L. Cusan, E.R. Suburu, P. Diamond, B. Candas, and F. Labrie. 1996. Effect of neoadjuvant endocrine therapy (combined androgen blockade) on normal prostate and prostatic carcinoma. Am. J. Surg. Pathol. 20:86-93.
49. Van der Krol, A.R., J.N.M. Mol, and A.R. Stuitje. 1988. Modulation of gene expression by complementary RNA or DNA sequences. Biotechniques. 6:958-976.
50. r 55,000 form of the human plasminogen activator, urokinase. J. Cell Biol. 100: 86-92.